Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Laparotomy, laparoscopy, cancer, and beyond
R. L. Whelan
Research output
:
Contribution to journal
›
Review article
›
peer-review
35
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Laparotomy, laparoscopy, cancer, and beyond'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Tumor
100%
Laparotomy
100%
Laparoscopy
100%
Oncological Outcomes
80%
Cancer Patients
60%
Laparoscopic Approach
60%
Tumor Cells
40%
Survival Benefit
40%
Curative Resection
40%
Adjuvant Therapy
20%
In Cancer
20%
Malignant Tumor
20%
Pharmacologic
20%
Study Support
20%
Immunosuppression
20%
Cancer Treatment
20%
Randomized Trial
20%
Resection
20%
Cancer Outcomes
20%
Conventional Chemotherapy
20%
Local Recurrence
20%
Surgical Technique
20%
Recurrence Rate
20%
Postoperative Period
20%
Negative Impact
20%
Immune Function
20%
Wound Healing
20%
Therapeutic Vaccine
20%
Tumor Immunotherapy
20%
Early Postoperative
20%
Nonrandomized Studies
20%
Minimally Invasive Technique
20%
Tumor Burden
20%
Immediate Postoperative
20%
Early Postoperative Period
20%
Cancer Resection
20%
Open Resection
20%
Impact of Surgery
20%
Middle Range
20%
Incisional
20%
Related Risk Factors
20%
Traumatization
20%
Murine Studies
20%
Anastomotic Healing
20%
Long Journey
20%
Tumor-specific Antibodies
20%
Medicine and Dentistry
Malignant Neoplasm
100%
Neoplasm
100%
Laparoscopic Surgery
100%
Laparotomy
100%
Surgery
66%
Recurrent Disease
50%
Immunotherapy
33%
Postoperative Period
33%
Tumor Cell
33%
Immunosuppressive Treatment
16%
Adjuvant Therapy
16%
Cancer Surgery
16%
Minimally Invasive Procedure
16%
Upregulation
16%
Recurrence Risk
16%
Wound
16%
Cancer Treatment
16%
Immune Function
16%
Surgical Procedure
16%
Tumor Vaccine
16%
Cancer Antibody
16%
Chemotherapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Neoplasm
100%
Recurrent Disease
37%
Immunotherapy
25%
Chemotherapy
12%
Recurrence Risk
12%
Wound
12%
Murine
12%
Tumor Vaccine
12%
Cancer Antibody
12%